Get started
Author

Peter Koelblinger

Development of encorafenib for BRAF-mutated advanced melanoma
2017 · Peter Koelblinger, Olaf Thuerigen, et al. · Current Opinion in Oncology · 192
A review of binimetinib for the treatment of mutant cutaneous melanoma
2017 · Peter Koelblinger, Joelle Dornbierer, et al. · Future Oncology · 58
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
2021 · Julia Maria Ressler, Matthias Karasek, et al. · Journal for ImmunoTherapy of Cancer · 51
PDF
Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
2020 · Maria-Filothei Lazaridou, Evamaria Gonschorek, et al. · OncoImmunology · 40
PDF
Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma
2017 · Aikaterini Tsiogka, Gerhard L. Jansky, et al. · Melanoma Research · 37
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies
2019 · Ines Pires da Silva, Isabella C. Glitza, et al. · Pigment Cell & Melanoma Research · 35
Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity
2022 · Daniela D. Weber, Sepideh Aminzadeh-Gohari, et al. · Cancer & Metabolism · 30
PDF
New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib
2018 · Peter Koelblinger, Roland Lang · OncoTargets and Therapy · 28
PDF
Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma
2020 · Maria-Filothei Lazaridou, Chiara Massa, et al. · Journal of Clinical Medicine · 27
PDF
Increased tumour cell PD ‐L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas
2018 · P. Koelblinger, M. Emberger, et al. · Journal of the European Academy of Dermatology and Venereology · 27
Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma ( NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies
2023 · R. Lang, T. Welponer, et al. · Journal of the European Academy of Dermatology and Venereology · 26
PDF
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial
2025 · Georgina V. Long, Charlie Garnett-Benson, et al. · Nature Medicine · 25
PDF
The impact of the COVID ‐19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres
2023 · Alexander Troesch, Magdalena Hoellwerth, et al. · Journal of the European Academy of Dermatology and Venereology · 23
COVID-19-Induced Reduction in Primary Melanoma Diagnoses: Experience from a Dermatopathology Referral Center
2021 · Magdalena Hoellwerth, Andreas Kaiser, et al. · Journal of Clinical Medicine · 23
PDF
Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts
2021 · Daniela D. Weber, Maheshwor Thapa, et al. · Cancers · 23
PDF
Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research
2023 · Magdalena Hoellwerth, Peter Koelblinger, et al. · Life · 22
PDF
The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
2020 · Corina Kaufmann, Werner Kempf, et al. · Histopathology · 21
PDF
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
2018 · N.P. Graf, P. Koelblinger, et al. · Journal of the European Academy of Dermatology and Venereology · 21
Beyond T cell toxicity – Intrathecal chemokine CXCL13 indicating B cell involvement in immune‐related adverse events following checkpoint inhibition: A two‐case series and literature review
2024 · Ferdinand Otto, Michael Seiberl, et al. · European Journal of Neurology · 18
PDF
Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab
2019 · Katharina Medek, Peter Koelblinger, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 18
Adjuvant anti‐PD‐1 antibody treatment in stage III/IV melanoma: real‐world experience and health economic considerations
2021 · Peter Koelblinger, Magdalena Hoellwerth, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 16
PDF
Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review
2024 · Magdalena Hoellwerth, Matthias Brandlmaier, et al. · Cancers · 14
PDF
MEK inhibition and immune responses in advanced melanoma
2017 · Reinhard Dummer, Egle Ramelyte, et al. · OncoImmunology · 14
PDF
Skin Manifestations of Outpatient Adverse Drug Events in the United States: A National Analysis
2013 · Peter Koelblinger, Tushar S. Dabade, et al. · Journal of Cutaneous Medicine and Surgery · 14
Wundheilungsstörungen während der antitumorösen Therapie mit Cetuximab bei schwerer generalisierter dystropher Epidermolysis bullosa
2019 · Katharina Medek, Peter Koelblinger, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 13
Works count: 71
Citation count: 937
H-index: 18
I10-index: 27
Year
Topic
Type